Gritstone bio, Inc. (GRTS)
After hours:
| Previous close | 0.7437 |
| Open | 0.7460 |
| Bid | 0.7301 x 1200 |
| Ask | 0.7431 x 1600 |
| Day's range | 0.7088 - 0.7750 |
| 52-week range | 0.6700 - 3.3300 |
| Volume | |
| Avg. volume | 2,917,880 |
| Market cap | 78.374M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.17 |
GlobeNewswireNature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) -- -- Publication underscores the important role of antigen selection and cassette design in the development of neoan
- GlobeNewswire
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences. Select events (marked by *) will be webcasted live and webcast details will be available on the ‘Events’ page of Gritstone bio’s website: https://ir.gritstonebio.com/investors/events. Archived replays will be
- GlobeNewswire
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILL
